{"TopicDetails": {"type": 0, "ccm2Id": 45032707, "cftId": 0, "identifier": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-02", "title": "Implementing adaptive platform trials", "publicationDateLong": 1652227200000, "callIdentifier": "HORIZON-JU-GH-EDCTP3-2022-01", "callTitle": "Research and Innovation actions supporting the global health EDCTP3 Joint Undertaking", "callccm2Id": 45032759, "allowPartnerSearch": true, "frameworkProgramme": {"id": 43108390, "abbreviation": "HORIZON", "description": "Horizon Europe Framework Programme (HORIZON)"}, "programmeDivision": [{"id": 43108557, "abbreviation": "HORIZON.2.1", "description": "Health"}, {"id": 43108541, "abbreviation": "HORIZON.2", "description": "Global Challenges and European Industrial Competitiveness"}], "topicMGAs": [], "tags": ["Diarrhoea", "treatments", "Antimicrobial resistance", "respiratory tract infections", "global health", "Africa", "emerging infections", "platform trials", "Neglected Infectious Diseases", "sub-Saharan Africa", "health", "Diarrhoeal", "re-emerging infections", "outbreak", "infectious diseases", "AMR", "epidemic", "adaptive platform trials", "lower respiratory tract infections"], "keywords": ["Antimicrobial resistance", "Africa", "Poverty related diseases", "Clinical trials", "Infectious diseases", "Neglected Infectious Diseases", "Emergent diseases", "Public health", "Emerging Epidemics", "Prevention and treatment of infection by pathogens", "Diarrhoeal diseases", "International Cooperation", "Interventional clinical trials", "Global health", "Respiratory systems", "Public health policies"], "flags": ["Africa", "EC-WORLD"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "typeOfMGA": [{"id": 43027846, "abbreviation": "HORIZON-AG", "description": "HORIZON Action Grant Budget-Based"}]}], "plannedOpeningDate": "11 May 2022", "submissionProcedure": {"id": 31094504, "abbreviation": "single-stage", "description": "single-stage"}, "deadlineDates": ["30 August 2022"]}], "latestInfos": [{"approvalDate": "Oct 7, 2022 10:57:19 AM", "lastChangeDate": "Oct 7, 2022 10:57:19 AM", "content": "<p><span lang=\"EN-IE\" style=\"font-size: 10.5pt; line-height: 107%; font-family: &quot;inherit&quot;, serif; color: rgb(51, 51, 51); border: 1pt none windowtext; padding: 0cm;\">Call </span><span lang=\"EN-IE\">HORIZON-JU-GH-EDCTP3-2022-01</span><span lang=\"EN-IE\" style=\"font-size: 10.5pt; line-height: 107%; font-family: &quot;inherit&quot;, serif; color: rgb(51, 51, 51); border: 1pt none windowtext; padding: 0cm;\"> closed on 30 August 2022. A total of 92 proposals were submitted. The breakdown per topic is:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 3.75pt 18.75pt; text-indent: -18pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-size:10.0pt;mso-bidi-font-size:10.5pt;font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">&middot;<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&quot;inherit&quot;,serif;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">HORIZON-JU-GH-EDCTP3-2022-CALL1-01-01: 40 proposals&nbsp;</span><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&#10;&quot;inherit&quot;,serif;mso-bidi-font-family:Calibri;color:#333333;border:none windowtext 1.0pt;&#10;mso-border-alt:none windowtext 0cm;padding:0cm;mso-ansi-language:EN-IE;&#10;mso-fareast-language:FR-BE\"><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 3.75pt 18.75pt; text-indent: -18pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-size:10.0pt;mso-bidi-font-size:10.5pt;font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">&middot;<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&quot;inherit&quot;,serif;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">HORIZON-JU-GH-EDCTP3-2022-CALL1-01-02: 14 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 3.75pt 18.75pt; text-indent: -18pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-size:10.0pt;mso-bidi-font-size:10.5pt;font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">&middot;<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&quot;inherit&quot;,serif;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">HORIZON-JU-GH-EDCTP3-2022-CALL1-01-03: 20 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 3.75pt 18.75pt; text-indent: -18pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-size:10.0pt;mso-bidi-font-size:10.5pt;font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">&middot;<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&quot;inherit&quot;,serif;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">HORIZON-JU-GH-EDCTP3-2022-CALL1-01-04:&nbsp; 2 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 3.75pt 18.75pt; text-indent: -18pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-size:10.0pt;mso-bidi-font-size:10.5pt;font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">&middot;<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&quot;inherit&quot;,serif;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">HORIZON-JU-GH-EDCTP3-2022-CALL1-01-05: 16 proposals<o:p></o:p></span></p>\r\n<p><span lang=\"EN-IE\" style=\"font-size:10.5pt;line-height:107%;font-family:&quot;inherit&quot;,serif;&#10;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-bidi-font-family:&#10;&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi;color:#333333;border:none windowtext 1.0pt;&#10;mso-border-alt:none windowtext 0cm;padding:0cm;mso-ansi-language:EN-IE;&#10;mso-fareast-language:FR-BE;mso-bidi-language:AR-SA\">Evaluation results are expected to be communicated on Friday 21 November 2022 at the earliest.</span></p>"}], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3418887": [{"action": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-05 - HORIZON-JU-CSA HORIZON JU Coordination and Support Actions", "plannedOpeningDate": "11 May 2022", "deadlineModel": "single-stage", "deadlineDates": ["30 August 2022"], "budgetYearMap": {"2022": 5000000}, "expectedGrants": 8, "minContribution": 600000, "maxContribution": 600000, "budgetTopicActionMap": {}}], "3418889": [{"action": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-04 - HORIZON-JU-CSA HORIZON JU Coordination and Support Actions", "plannedOpeningDate": "11 May 2022", "deadlineModel": "single-stage", "deadlineDates": ["30 August 2022"], "budgetYearMap": {"2022": 1000000}, "expectedGrants": 1, "minContribution": 1000000, "maxContribution": 1000000, "budgetTopicActionMap": {}}], "3418891": [{"action": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-02 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "11 May 2022", "deadlineModel": "single-stage", "deadlineDates": ["30 August 2022"], "budgetYearMap": {"2022": 30850000}, "expectedGrants": 5, "minContribution": 6000000, "maxContribution": 8000000, "budgetTopicActionMap": {}}], "3418893": [{"action": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-03 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "11 May 2022", "deadlineModel": "single-stage", "deadlineDates": ["30 August 2022"], "budgetYearMap": {"2022": 22000000}, "expectedGrants": 4, "minContribution": 5000000, "maxContribution": 5000000, "budgetTopicActionMap": {}}], "3418895": [{"action": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-01 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "11 May 2022", "deadlineModel": "single-stage", "deadlineDates": ["30 August 2022"], "budgetYearMap": {"2022": 38030000}, "expectedGrants": 9, "minContribution": 4000000, "maxContribution": 4000000, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2022"]}, "description": "<SPAN class=\"topicdescriptionkind\">ExpectedOutcome</SPAN>:<p>This topic aims at supporting activities that are contributing to one or several of the expected impacts for this call. To that end, proposals under this topic should aim for delivering results that are contributing to all the following expected outcomes:</p><ul level=\"0\"><li>More clinicians and researchers in sub-Saharan Africa have the capacity to design, implement and maintain large-scale, multi-centre and multi-country adaptive platform trials allowing the simultaneous evaluation of multiple interventions in an adaptive manner;</li><li>A number of large-scale, multi-centre and multi-country adaptive platform trials, investigating treatments and/or treatment regimens for infectious diseases are implemented in sub-Saharan Africa, having the operational capability to rapidly include treatment approaches for infectious diseases outbreaks with epidemic or pandemic potential;</li><li>Health care providers and professionals in sub-Saharan Africa have a better understanding on how to treat and reduce the burden of infectious diseases within the scope of the GH EDCTP3 programme in this call topic;</li><li>Trial sites across multiple institutions and countries belong to a coordinated network of clinical sites and facilities such as research laboratories with the capacity to deliver efficiently robust clinical evidence derived from a diverse population, through harmonized research methods, data collection and sharing and joint analysis;</li><li>More clinical investigators and researchers at the earlier stages of their career (e.g. Master\u2019s, PhD candidates, or post-doctoral level), including increasing proportions of women scientists, are able to develop a scientific career in sub-Saharan Africa and establish themselves as scientific leaders in sub-Saharan Africa.</li> </ul>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>During the COVID-19 pandemic the research community has seen the emergence and success of large-scale, multi-country adaptive platform trials to evaluate therapeutics for COVID-19. Adaptive platform trials have the ability to evaluate simultaneously multiple interventions in one trial answering multiple questions based on a master protocol<sup><a target=_self href=#fn1 id=r1>[1]</a></sup>. The adaptive design of the trial provides the flexibility for promising new therapies to enter clinical evaluation and for poor-performing ones to discontinue based on interim evaluations, paving a pathway for efficient clinical trial research. Adaptive platform trials help to establish an efficient research ecosystem that can build clinical trial capacity for long-term sustainability in a coordinated and collaborative manner across institutions in different countries.</p><p>The COVID-19 pandemic has shown a lack of COVID-19-related large-scale clinical trials in sub-Saharan Africa, while this region could greatly benefit from more resource-efficient clinical trials that are investigating novel treatments for existing infectious diseases and that are able to react to future threats. Implementation of adaptive platform trials in sub-Saharan Africa has the potential to improve the identification of safe and efficacious interventions and save resources that are particularly scarce in this region of the world. In addition, the conduct of adaptive platform trials with the in-built operational ability to rapidly implement clinical evaluation of treatment options for when an epidemic-prone pathogen strikes, is key to being prepared for infectious disease epidemics or pandemics.</p><p>This topic aims to support the implementation of adaptive platform trials for the evaluation of candidate treatments for infectious diseases in sub-Saharan Africa. These trials should also be able to rapidly evaluate treatments in response to an emerging infectious disease threat.</p><p>Pathogens within the scope of this call topic are those that cause lower respiratory tract infections, emerging and re-emerging infections, neglected infectious diseases, and diarrheal diseases. Special attention should be paid to infections that lack treatment options or where treatments are inadequate. This includes for example infections that are hard to treat due to antimicrobial resistance. HIV, malaria and tuberculosis are excluded from this call topic due to previous investments in these areas.</p><p>As appropriate, using rapid multiplex platforms for diagnosis of parasitic, bacterial, fungal and/or viral infections should be considered,</p><p>The proposals should address <strong>all</strong> of the following:</p><ul level=\"0\"><li>Implementation of adaptive platform trials in sub-Saharan Africa that are routinely evaluating treatment options for infectious diseases within the scope of this topic in \u2018inter-epidemic\u2019 times, while also considering in their trial design the ability to be \u2018epidemic-fit\u2019 and ready for the timely assessment of treatments in the face of an infectious diseases outbreak with epidemic or pandemic potential;</li><li>Training on clinical trial implementation and laboratory analysis, harmonized data collection and management systems to run the adaptive platform trials and at the same time create a coordinated network of clinical trial sites and research laboratories for longer-term usability;</li><li>Hurdles related to ethical, administrative, regulatory and logistical aspects should be addressed in order to allow smooth implementation of adaptive platform trials and avoid such barriers when the trial needs to adapt in response to an epidemic or pandemic;</li><li>Outreach to sub-Saharan African clinical researchers and biostatisticians to build and increase the capacity for the design and implementation of further adaptive platform trials across sub\u2013Saharan Africa;</li><li>Promotion of close communication between clinical experts, patient communities, regulators, health care workers and policy makers to increase understanding of and trust in adaptive platform trials as an efficient design for clinical research in sub-Saharan Africa;</li><li>Interaction with relevant national public health institutes, Africa CDC, World Health Organisation - Regional Office for Africa and/or other regional and international relevant organisations to adequately address health research systems needs in adaptive platform trial study design;</li><li>Sex and gender aspects should be taken into account. All data should be disaggregated by sex, age and other relevant variables, such as by measures of socioeconomic status (i.e. take into account the socioeconomic gradient).</li> </ul><p>Populations for intervention development and evaluation should also include vulnerable populations which need treatment options, including children, pregnant women, people with co-infections and co-morbidities, older people, and people living in hard-to-reach communities.</p><p>Collaboration and coordination with existing adaptive platform trials in Africa and Europe, EDCTP\u2019s Networks of Excellence and other EDCTP funded initiatives is expected, where relevant.</p>\n<SPAN class=\"topicdescriptionkind\">Cross-cutting Priorities</SPAN>:<p><a href=\"//ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-search;statusCodes=31094501,31094502,31094503;programCcm2Id=43108390;crossCuttingPriorityCode=Africa;sortQuery=sortStatus;orderBy=asc\">Africa</a><br><a href=\"//ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-search;statusCodes=31094501,31094502,31094503;programCcm2Id=43108390;crossCuttingPriorityCode=EC-WORLD;sortQuery=sortStatus;orderBy=asc\">International Cooperation</a><br></p>\n<p id=fn1><a  target=_self href=#r1>[1]</a>https://www.nature.com/articles/s41573-019-0034-3.pdf</p>", "conditions": "<p><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:115%;&#10;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:&#10;Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;&#10;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi;&#10;color:#404040;mso-themecolor:text1;mso-themetint:191;mso-ansi-language:EN-US;&#10;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">General conditions</span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">1. Admissibility conditions: </span></b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;&#10;mso-bidi-font-weight:bold\">described in </span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex A</a></span></span><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:&#10;bold\"> and </span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#10;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex E</a></span></span><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:&#10;bold\"> of the Horizon Europe Work Programme General Annexes</span></p>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\">&nbsp;</p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">Proposal page limits and layout:</span></b><span lang=\"EN-US\" style=\"mso-ansi-language:&#10;EN-US\"> described in Part B of the Application Form available in the Submission System</span></p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>\n<p><b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">2. Eligible countries:</span></b></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\">According to Article 110 of the Council Regulation (EU) 2021/2085, funding from the&nbsp; Global Health EDCTP3 Joint Undertaking is restricted to legal entities established in Member States or associated countries or in the constituent states of the EDCTP Association.</span>&nbsp;</p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"font-size:11.0pt;line-height:107%;font-family:&quot;Calibri&quot;,sans-serif;&#10;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:&#10;minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-IE;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\">Constituent states of the EDCTP Association that are not Member States or associated countries are: Burkina Faso, Cameroon, Congo, C&ocirc;te d&rsquo;Ivoire, Ethiopia, Gabon, The Gambia, Ghana,&nbsp;</span><span style=\"font-family: Calibri, sans-serif; font-size: 14.6667px;\">Kenya,</span><span style=\"font-family: Calibri, sans-serif; font-size: 14.6667px;\">&nbsp;</span><span style=\"font-family: Calibri, sans-serif; font-size: 11pt;\">Mali, Mozambique, Niger, Nigeria, Senegal, South Africa, Tanzania, Uganda, United Kingdom, Zambia.</span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\" style=\"mso-ansi-language:&#10;EN-US\"><span lang=\"EN-US\" style=\"font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px;\">A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the&nbsp;</span><span class=\"MsoHyperlink\" style=\"font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">Horizon Europe Programme Guide</a></span><span lang=\"EN-US\" style=\"font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px;\">.</span>.</span></p>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">3<span style=\"mso-bidi-font-weight:bold\">. Other eligibility conditions:</span></span></b><span lang=\"EN-US\" style=\"mso-ansi-language:&#10;EN-US\"> described in </span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#10;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex B</a></span></span><span style=\"mso-ansi-language:EN-US\"> <span lang=\"EN-US\">of the Work Programme General Annexes,&nbsp;</span></span><span style=\"font-family: Calibri, sans-serif; font-size: 11pt;\">except for the specific conditions for GH EDCTP3 funding as regards </span><u style=\"font-family: Calibri, sans-serif; font-size: 11pt;\">Entities eligible for funding</u><span style=\"font-family: Calibri, sans-serif; font-size: 11pt;\"> and </span><u style=\"font-family: Calibri, sans-serif; font-size: 11pt;\">Consortium composition.</u></p>\r\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"mso-ansi-language:EN-IE\">Entities eligible to participate<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"mso-ansi-language:EN-IE\">Given the illegal invasion of Ukraine by Russia and the involvement of Belarus, there is currently no appropriate context allowing the implementation of the actions foreseen in this programme with legal entities established in Russia, Belarus, or in non-government controlled territories of Ukraine. Therefore, such legal entities are not eligible to participate in any capacity. This criterion also applies in cases where the action involves financial support given by grant beneficiaries to third parties established in Russia, Belarus or in non-government controlled territories of Ukraine (in accordance with Article 204 of the Financial Regulation No 2018/1046).<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"mso-ansi-language:EN-IE\"><o:p>&nbsp;</o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"mso-ansi-language:EN-IE\">Entities eligible for funding<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"mso-ansi-language:EN-IE\">To be eligible for funding, applicants must be eligible to participate and established in one of the eligible countries, i.e.<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"mso-ansi-language:EN-IE\"><o:p>&nbsp;</o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"mso-ansi-language:EN-IE\">-<span style=\"mso-spacerun:yes\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The Member States of the European Union, including their outermost regions;<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"mso-ansi-language:EN-IE\">-<span style=\"mso-spacerun:yes\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The Oversees Countries and Territories (OCTs) linked to Member States<a style=\"mso-footnote-id:ftn1\" href=\"#_ftn1\" name=\"_ftnref1\" title=\"\"><span class=\"MsoFootnoteReference\"><span style=\"mso-special-character:footnote\"><!--[if !supportFootnotes]--><span class=\"MsoFootnoteReference\"><span lang=\"EN-IE\" style=\"font-size:11.0pt;line-height:&#10;107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;&#10;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:&#10;minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">[1]</span></span><!--[endif]--></span></span></a><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"mso-ansi-language:EN-IE\">-<span style=\"mso-spacerun:yes\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Eligible non-EU countries:<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"mso-ansi-language:EN-IE\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; o<span style=\"mso-spacerun:yes\">&nbsp;&nbsp; </span>Countries associated to Horizon Europe<a style=\"mso-footnote-id:ftn2\" href=\"#_ftn2\" name=\"_ftnref2\" title=\"\"><span class=\"MsoFootnoteReference\"><span style=\"mso-special-character:footnote\"><!--[if !supportFootnotes]--><span class=\"MsoFootnoteReference\"><span lang=\"EN-IE\" style=\"font-size:11.0pt;line-height:&#10;107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;&#10;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:&#10;minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">[2]</span></span><!--[endif]--></span></span></a><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"mso-ansi-language:EN-IE\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; o<span style=\"mso-spacerun:yes\">&nbsp;&nbsp; </span>Countries that are members of the EDCTP Association<a style=\"mso-footnote-id:ftn3\" href=\"#_ftn3\" name=\"_ftnref3\" title=\"\"><span class=\"MsoFootnoteReference\"><span style=\"mso-special-character:&#10;footnote\"><!--[if !supportFootnotes]--><span class=\"MsoFootnoteReference\"><span lang=\"EN-IE\" style=\"font-size:11.0pt;line-height:107%;font-family:&quot;Calibri&quot;,sans-serif;&#10;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:&#10;minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-IE;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\">[3]</span></span><!--[endif]--></span></span></a><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"mso-ansi-language:EN-IE\"><o:p>&nbsp;</o:p></span></p>\r\n<p><span lang=\"EN-IE\" style=\"font-size:11.0pt;line-height:107%;font-family:&quot;Calibri&quot;,sans-serif;&#10;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:&#10;minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-IE;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\">Legal entities which are established in countries not listed above will be eligible for funding if provided for in the specific call conditions, or if the participation is considered essential for implementing the action by the granting authority.</span></p>\r\n<div style=\"mso-element:footnote-list\"><!--[if !supportFootnotes]--><br clear=\"all\" />\r\n<hr align=\"left\" size=\"1\" width=\"33%\" />\r\n<!--[endif]-->\r\n<div style=\"mso-element:footnote\" id=\"ftn1\">\r\n<p class=\"MsoFootnoteText\"><a style=\"mso-footnote-id:ftn1\" href=\"#_ftnref1\" name=\"_ftn1\" title=\"\"><span class=\"MsoFootnoteReference\"><span style=\"mso-special-character:&#10;footnote\"><!--[if !supportFootnotes]--><span class=\"MsoFootnoteReference\"><span style=\"font-size:10.0pt;line-height:107%;font-family:&quot;Calibri&quot;,sans-serif;&#10;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:&#10;minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-theme-font:minor-bidi;mso-ansi-language:FR-BE;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\">[1]</span></span><!--[endif]--></span></span></a> <span lang=\"EN-IE\">Entities from Oversees Countries and Territories (OCT) are eligible for funding under the same conditions as entities from the Member State to which the OCT in question is linked. See the <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\" target=\"_blank\">Horizon Europe Programme Guide</a> for a complete list of OCTs.<o:p></o:p></span></p>\r\n</div>\r\n<div style=\"mso-element:footnote\" id=\"ftn2\">\r\n<p class=\"MsoFootnoteText\"><a style=\"mso-footnote-id:ftn2\" href=\"#_ftnref2\" name=\"_ftn2\" title=\"\"><span class=\"MsoFootnoteReference\"><span style=\"mso-special-character:&#10;footnote\"><!--[if !supportFootnotes]--><span class=\"MsoFootnoteReference\"><span style=\"font-size:10.0pt;line-height:107%;font-family:&quot;Calibri&quot;,sans-serif;&#10;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:&#10;minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-theme-font:minor-bidi;mso-ansi-language:FR-BE;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\">[2]</span></span><!--[endif]--></span></span></a> <span lang=\"EN-IE\">See list of <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratom_en.pdf\" target=\"_blank\">Associated Countries</a> and <a href=\"https://ec.europa.eu/info/research-and-innovation/strategy/strategy-2020-2024/europe-world/international-cooperation_en\" target=\"_blank\">International Cooperation</a></span></p>\r\n<p class=\"MsoFootnoteText\"><a href=\"#_ftnref3\" name=\"_ftn3\" title=\"\"><span class=\"MsoFootnoteReference\"><span class=\"MsoFootnoteReference\"><span style=\"font-size:10.0pt;line-height:107%;font-family:&quot;Calibri&quot;,sans-serif;&#10;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:&#10;minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-theme-font:minor-bidi;mso-ansi-language:FR-BE;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\">[3]</span></span></span></a> See the <a href=\"http://www.edctp.org/about-us/governance/general-assembly/members-of-the-general-assembly/\">EDCTP website</a></p>\r\n</div>\r\n<div style=\"mso-element:footnote\" id=\"ftn3\">\r\n<p class=\"MsoFootnoteText\"><o:p></o:p></p>\r\n</div>\r\n</div>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\"><b>4. Financial and operational capacity and exclusion: </b><span style=\"mso-bidi-font-weight:bold\">described in <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex C</a> of the Work Programme General Annexes</span></p>\r\n<p>&nbsp;</p>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\"><b><span lang=\"FR-BE\" style=\"mso-ansi-language:FR-BE\">5.&nbsp;Evaluation and award:</span></b></p>\r\n<p>&nbsp;</p>\n<div>\r\n<ul type=\"square\" style=\"margin-top: 0cm;\">\r\n    <li class=\"MsoNormal\"><b><span lang=\"EN-US\">Award criteria&nbsp;</span></b><span lang=\"EN-US\">&nbsp;are described in&nbsp;</span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex D</a></span><span lang=\"EN-US\">&nbsp;of the Work Programme General Annexes.</span></li>\r\n    <li class=\"MsoNormal\">\r\n    <p class=\"MsoNormal\"><strong><span lang=\"EN-US\">Scoring and thresholds</span></strong><span lang=\"EN-US\"> are as follows:<o:p></o:p></span></p>\r\n    <p class=\"MsoNormal\" style=\"text-align: justify;\"><span lang=\"EN-IE\">Evaluation scores will be awarded for the criteria, and not for the different aspects listed in the table. For full applications, each criterion will be scored out of 5. The threshold for individual criteria 1 (Excellence) and 2 (Impact) will be 4 and for criteria 3 (Quality and efficiency of the implementation) will be 3. The overall threshold, applying to the sum of the three individual scores, will be 12.<o:p></o:p></span></p>\r\n    <span lang=\"EN-IE\" style=\"font-size: 11pt; line-height: 15.6933px; font-family: Calibri, sans-serif;\">Proposals that pass the individual threshold AND the overall threshold will be considered for funding, within the limits of the available call budget. Other proposals will be rejected.</span></li>\r\n</ul>\r\n</div>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\"><b><span lang=\"EN-US\">Submission and evaluation      processes</span></b><span lang=\"EN-US\"> are      described in </span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex      F</a></span><span lang=\"EN-US\"> of      the Work Programme General Annexes and the </span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\">Online      Manual</a><span lang=\"EN-US\"><o:p></o:p></span></li>\r\n</ul>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\"><b><span lang=\"EN-US\">Indicative timeline for      evaluation and grant agreement: </span></b><span lang=\"EN-US\">described in </span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex      F</a></span><span lang=\"EN-US\"> of the Work Programme General Annexes</span><span lang=\"EN-US\"><o:p></o:p></span></li>\r\n</ul>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">6. Legal and financial set-up of the grants: </span></b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">described in </span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:&#10;minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex G</a></span></span><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\"> of the Work Programme General Annexes<o:p></o:p></span></p>\r\n<p>&nbsp;</p>\n<p>Implementing the provision on affordable access as defined in Article 114 of the 2021/2085 Council Regulation establishing the Joint Undertakings under Horizon Europe[[Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014; OJ L 427, 30.11.2021, p. 17]], grants award under this topic will have to submit the following deliverables:</p><p>1. Stewardship plan</p><p>Beneficiaries must prepare stewardship plans outlining how to achieve the optimal use of an intervention, including, for example, how to avoid irrational use, overuse or abuse of health technologies (e.g. antimicrobials). A draft plan must be submitted after half the duration of the project has elapsed and a final plan must be submitted with the final report.</p><p>2. Global access plan</p><p>With the final report, beneficiaries must submit an appropriate and proportionate global access plan that covers registration targets, plans to meet demand, flexible approaches to IP and other strategies that reflect ability to pay and ensure that economic barriers to access are low.</p>\n<p>Also in line with Article 114 of the 2021/2085 Council Regulation<u>, </u>participants will be subject to the following additional exploitation obligations:</p><ol level=\"0\">  <li>Participants must \u2013 up to four years after the end of the action (see Data Sheet, Point 1) \u2013 use their best efforts to ensure that resulting health technologies and services will be broadly available and accessible, as soon as possible and at fair and reasonable conditions. In this respect, if, despite a participants\u2019 best efforts, the results are not exploited within one year after the end of the action, participants must (unless otherwise agreed in writing with the granting authority) use the Horizon Results Platform to find interested parties to exploit the results.</li><li>In case the participants cannot fulfil the preceding obligation, the participants must (if requested by the granting authority) grant non-exclusive licences - under fair and reasonable conditions - to their results to legal entities that commit to rapidly and broadly exploiting the resulting health technologies and services and ensure that they are broadly available and accessible, as soon as possible and at fair and reasonable conditions.</li> </ol><p>In case of transfer of the ownership or licensing of results, participants must pass on such additional exploitation obligations to the legal entities exploiting the results.</p><p>For up to four years after the action (see Data Sheet, Point 1), the funding body must be informed every year about the status of the development of the product or any other exploitation of the results through an annual report that is due on each anniversary of the end of the grant agreement.</p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:&#10;11.0pt;line-height:115%;mso-ansi-language:EN-US\">Specific conditions<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\">7. Specific conditions: </span></b><span lang=\"EN-US\">described in the specific topic of the Work Programme<o:p></o:p></span></p>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:&#10;11.0pt;line-height:115%;mso-ansi-language:EN-US\">Documents<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">Call documents:<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:bold\">Standard application form &mdash;<i style=\"mso-bidi-font-style:normal\"> call-specific application form is available in the Submission System</i><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/af_he-ria-ia_en.pdf\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin\">Standard application form (HE RIA, IA)</span></a><span style=\"color:#404040;mso-themecolor:&#10;text1;mso-themetint:191;mso-ansi-language:EN-US;mso-bidi-font-weight:bold\"> <span lang=\"EN-US\"><o:p></o:p></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"color:#404040;mso-themecolor:text1;mso-themetint:191;&#10;mso-ansi-language:EN-US;mso-bidi-font-weight:bold\">Standard evaluation form </span><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:bold\">&mdash;<i style=\"mso-bidi-font-style:normal\"> will be used with the necessary adaptations</i><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/ef/ef_he-ria-ia_en.pdf\"><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:bold\">Standard evaluation form (HE RIA, IA)</span></a><span lang=\"EN-US\" style=\"color:#404040;&#10;mso-themecolor:text1;mso-themetint:191;mso-ansi-language:EN-US;mso-bidi-font-weight:&#10;bold\"> <o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"color: rgb(64, 64, 64);\">MGA</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt;tab-stops:&#10;191.4pt\"><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-weight:bold\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/agr-contr/general-mga_horizon-euratom_en.pdf\">HE <span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">General MGA v1.1</span></a></span></span><span class=\"MsoHyperlink\"><span style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:&#10;bold\"> <span lang=\"EN-US\"><o:p></o:p></span></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt;tab-stops:&#10;191.4pt\"><span style=\"color: rgb(64, 64, 64);\">Call-specific instructions</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"color:#404040;mso-themecolor:text1;mso-themetint:191;&#10;mso-ansi-language:EN-US;mso-bidi-font-weight:bold\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/information-on-clinical-studies_he_en.docx\" target=\"_blank\">Information on clinical studies (HE)</a>&nbsp;<o:p></o:p></span><span style=\"background-color: rgb(198, 219, 239); font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px;\">(only for proposals including clinical studies)</span></p>\r\n<p>&nbsp;</p>\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><b><span lang=\"EN-US\">Additional documents:<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\">&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"padding: 3px 0px; margin: 0px 0px 0.0001pt; line-height: 1.5; font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px; background-color: rgb(198, 219, 239);\"><a href=\"https://ec.europa.eu/info/sites/default/files/research_and_innovation/research_by_area/documents/ec_rtd_global-health-edctp3-wp-annex1.pdf\" target=\"_blank\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">GH EDCTP3 JU Work Programme 2022</a></p>\r\n<p class=\"MsoNormal\" style=\"padding: 3px 0px; margin: 0px 0px 0.0001pt; line-height: 1.5; font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px; background-color: rgb(198, 219, 239);\"><b><span lang=\"EN-US\"><o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"padding: 3px 0px; margin: 0px 0px 0.0001pt; line-height: 1.5; font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px; background-color: rgb(198, 219, 239);\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">HE Main Work Programme 2021&ndash;2022 &ndash; 13. General Annexes</a></p>\r\n<p class=\"MsoNormal\" style=\"padding: 3px 0px; margin: 0px 0px 0.0001pt; line-height: 1.5; font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px; background-color: rgb(198, 219, 239);\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/rules-lev-lear-fca_en.pdf\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment</a></p>\r\n<p class=\"MsoNormal\" style=\"padding: 3px 0px; margin: 0px 0px 0.0001pt; line-height: 1.5; font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px; background-color: rgb(198, 219, 239);\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/aga_en.pdf\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\"><span lang=\"EN-US\">EU Grants AGA&nbsp;</span>&mdash; Annotated Model Grant Agreement</a></p>\r\n<p class=\"MsoNormal\" style=\"padding: 3px 0px; margin: 0px 0px 0.0001pt; line-height: 1.5; font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px; background-color: rgb(198, 219, 239);\">&nbsp;</p>\r\n<ul style=\"padding: 0px; margin: 3px 0px 3px 30px; font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px; background-color: rgb(198, 219, 239);\">\r\n    <li style=\"padding: 0px; margin: 0px; color: rgb(51, 51, 51); line-height: 1.4; list-style-type: square;\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv%3AOJ.L_.2021.427.01.0017.01.ENG&amp;toc=OJ%3AL%3A2021%3A427%3ATOC\" target=\"_blank\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">GH EDCTP3 JU Regulation of Establishment</a></li>\r\n    <li style=\"padding: 0px; margin: 0px; color: rgb(51, 51, 51); line-height: 1.4; list-style-type: square;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\" target=\"_blank\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">HE Programme guide</a></li>\r\n    <li style=\"padding: 0px; margin: 0px; color: rgb(51, 51, 51); line-height: 1.4; list-style-type: square;\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R0695\" target=\"_blank\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">HE Framework Programme and rules for Participation Regulation&nbsp; 2021/695</a></li>\r\n    <li style=\"padding: 0px; margin: 0px; color: rgb(51, 51, 51); line-height: 1.4; list-style-type: square;\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021D0764\" target=\"_blank\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">HE Specific Programme Decision 2021/764</a></li>\r\n    <li style=\"padding: 0px; margin: 0px; color: rgb(51, 51, 51); line-height: 1.4; list-style-type: square;\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32018R1046&amp;qid=1535046024012\" target=\"_blank\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">EU Financial Regulation</a>&nbsp;</li>\r\n</ul>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\">&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span lang=\"EN-US\">Funding &amp; Tenders Portal Online Manual</span></a><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/tc_en.pdf\">Funding &amp; Tenders Portal Terms and Conditions</a><o:p></o:p></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size:11.0pt;line-height:115%;font-family:&quot;Calibri&quot;,sans-serif;&#10;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:&#10;minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/privacy-statement_en.pdf\">Funding &amp; Tenders Portal Privacy Statement</a></span></p>", "supportInfo": "<p><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;font-weight:normal;mso-bidi-font-weight:bold\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><b>Online Manual&nbsp;</b></a></span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">is your guide on the procedures from proposal submission to managing your grant.<o:p></o:p></span></p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Horizon Europe Programme Guide</span></b></a><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;</span></strong><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif; font-weight: normal;\">contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;type=undefined;categories=;programme=H2020;actions=;keyword=\" target=\"_blank\">Funding &amp; Tenders Portal FAQ</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/research-and-innovation/contact/research-enquiry-service_en\" target=\"_blank\">Research Enquiry Service</a></span>&nbsp;</b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.</span></p>\r\n<p><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp\" target=\"_blank\">National Contact Points (NCPs)</a>&nbsp;</span></b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (&lsquo;third-countries&rsquo;).<b><o:p></o:p></b></span></p>\r\n<p><a href=\"https://een.ec.europa.eu/\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Enterprise Europe Network</span></b></a><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;color:#003366\">&nbsp;</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form\" target=\"_blank\">IT Helpdesk</a></span></b>&nbsp;</span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash;&nbsp;contact the Funding &amp; Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://www.iprhelpdesk.eu/\" target=\"_blank\">European IPR Helpdesk</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;assists you on intellectual property issues.<br />\r\n<br />\r\n</span><b><a href=\"mailto:research@cencenelec.eu\" target=\"_blank\">CEN-CENELEC Research Helpdesk</a> and <a href=\"https://www.etsi.org/research/helpdesk\" target=\"_blank\">ETSI Research Helpdesk</a></b>&nbsp;<span style=\"font-family: Arial, sans-serif;\">&ndash;&nbsp;&nbsp;</span>the European Standards Organisations&nbsp;advise you how to tackle standardisation in your project proposal.&nbsp;&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"margin-left:36.0pt\"><o:p></o:p></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://euraxess.ec.europa.eu/sites/default/files/am509774cee_en_e4.pdf\" target=\"_blank\">The European Charter for Researchers and the Code of Conduct for their recruitment</a></span></b></span><strong><u><span style=\"font-size:&#10;9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366\"> </span></u></strong><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366;font-weight:&#10;normal;mso-bidi-font-weight:bold\">&ndash; consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.</span></strong><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></b></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search\" target=\"_blank\">Partner Search Services</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;help you find a partner organisation for your proposal.<o:p></o:p></span></p>\r\n<p>&nbsp;</p>", "sepTemplate": "<p>To access the Electronic Submission Service, please click on the submission-button next to the <strong>type of action</strong> and the <strong>type of model grant agreement</strong> that corresponds to your proposal. You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Funding &amp; Tenders Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"additionalInfo": "", "staticAdditionalInfo": "<p>The general conditions relating to this call are those applicable to the 2021/2022 work programme of Global Health EDCTP3 outlined above.</p><p><u>Expected impacts of Call 1</u></p><p>Activities funded under this call for proposals should contribute to:</p><ul level=\"0\"><li>Achieve SDG3 \u2018Ensure healthy lives and promote well-being for all at all ages\u2019 in sub-Saharan African countries;</li><li>Provide evidence for informed health policies and guidelines within public health systems in sub-Saharan Africa and at international level;</li><li>Strengthen clinical research capability in sub-Saharan Africa to rapidly respond to emerging epidemics;</li><li>Enable a regulatory environment that can ensure effective development, delivery, and uptake of new or improved safe health technologies guaranteeing that trials in sub-Saharan African countries meet international standards;</li><li>Enable countries in sub-Saharan Africa to better understand pathogen epidemiology and support effective public health monitoring through integration of genomics and epidemiology;</li><li>Increase cost effectiveness of public investment through collaboration of funders of clinical trials in the area of infectious diseases in sub-Saharan Africa;</li><li>Strengthen health systems to ensure uptake of effective health technologies and innovations;</li><li>Enhance sustainable global scientific collaboration in health research and international cooperation across sub-Saharan Africa.</li> </ul>\n", "latestInfos": [{"approvalDate": "Dec 22, 2022 8:21:02 AM", "lastChangeDate": "Dec 22, 2022 8:21:02 AM", "content": "<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">Information for the Funding Portal<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">Number proposals submitted: 92<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">Number Ineligible proposals: 11<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">Number proposals evaluated: 81<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Number of Below threshold: 36<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Number of Above threshold: 45<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Number of Main list: 26<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Number of Reserve list: 4<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Number rejected due to budgetary ressources: 15<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\">&nbsp;</p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">Number of proposal upgraded from Reserve list to Main list: 1</span></b><span lang=\"EN-IE\"><o:p></o:p></span></p>"}, {"approvalDate": "May 17, 2022 4:30:46 PM", "lastChangeDate": "May 17, 2022 4:30:46 PM", "content": "The submission session is now available for: HORIZON-JU-GH-EDCTP3-2022-CALL1-01-01(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2022-CALL1-01-04(HORIZON-JU-CSA), HORIZON-JU-GH-EDCTP3-2022-CALL1-01-03(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2022-CALL1-01-02(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2022-CALL1-01-05(HORIZON-JU-CSA)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}